University at Buffalo - The State University of New York
Skip to Content
Nan                            Zhang

Nan Zhang MD, PhD

Department of Pathology and Anatomical Sciences

Clinical Assistant Professor

Specialty/Research Focus

Anatomic Pathology; Clinical Pathology

Professional Summary:

I am a board-certified pathologist. I‘m serving the Kaleida Health laboratories primarily in the fields of hematology/hematopathology and transfusion medicine.

My research experiences includes both basic immunology and translational research involving antibody engineering, lymphoma and solid tumor immunotherapy, lymphoma characterization, leukemic bone marrow microenvironment studies, as well as general clinical pathology research.

My previous research was focused on using different antibody-based strategies to generate novel reagents for cancer immunotherapy. For example, based on the observation that the induction of apoptosis in lymphoma cells requires proper presentation of anti-CD20, we have generated a novel Rituximab Polymer that induces apoptosis in non-Hodgkin’s lymphoma cells. Bio-distribution study has shown that this polymer targeted Burritt’s lymphoma cells in mouse xenograft model. Immunotherapeutic study has demonstrated that systemic delivery of this polymer successfully induced tumor regression in vivo. Moreover, we found that some anti-HLA-DR monoclonal antibody and its humanized form are also potent apoptosis inducers on lymphoma cells. We also showed that tumor targeting antibodies fused with T-cell co-stimulators presented increased tumor uptake. Systemic administration of this combination induced tumor regression significantly and prolonged the survival of treated mice.

Currently, my research focuses on the characterization of follicular lymphoma with marginal zone differentiation. Follicular lymphoma (FL) with marginal zone differentiation is a relatively rare morphologic variant of FL. We tried to characterize the clinicopathologic features as well as survival studies. We found that this morphology correlates with complex cytogenetic abnormalities and associated with worse clinical outcome compared with follicular lymphoma without marginal zone differentiation. Recognizing this variant is important in patient treatment and prognosis.

Another focus of my currently ongoing studies is about the bone marrow microenvironment in leukemic and aleukemic acute myeloid leukemia (AML). Aleukemic AML differs from leukemic AML in that the peripheral blood show high blast counts. Little is understood why in certain AML, the bone marrow releases high number of blasts into the peripheral blood. Our hypothesis is that there is a bone marrow-sinusoids gate that controls the release of hematopoietic cells into peripheral blood, including the immature precursor cells. This gate can be affected by the changes in bone marrow microenvironment including aberrant expression of certain adhesion molecules and a variety of depositions in the stroma by AML. This hypothesis is supported by the fact that in many previous studies, only high blast counts in the peripheral blood correlates with worse prognosis in AML. I believe further exploration along this direction will gain us more valuable information about AML pathophysiology.

I have also been actively involved in undergraduate student, medical student, and junior resident teaching and training during all these years of my career development. I enjoyed sharing my thoughts and experiences with them and often times, I learn a lot from these interactions.

Education and Training:
  • Fellowship, Hematopathology, City of Hope National Medical Center (2014)
  • Resident, University at Buffalo (2013)
  • Resident, Cedars-Sinai Medical Center (2011)
  • Post-doctoral Fellow, Immunology, City of Hope National Medical Center (2009)
  • PhD, Immunology and Pathobiology, University of Southern California (2006)
  • MB, Peking University (2000)
Awards and Honors:
  • Teacher of the Year Award, Pathology Residency Program, University at Buffalo, SUNY (2016)

Journal Articles:
Evaluative Studies and Case Reports:

  • "Follicular lymphoma with marginal zone differentiation, an institutional experience," United States and Canadian Academy of Pathology (USCAP) Annual Conference, USCAP (2014)
  • "Nodal Marginal Zone Lymphoma with Aberrant CD10 Expression" merican Society for Clinical Pathology (ASCP) Annual Conference, ASCP (2013)
  • "Generation of Rituximab Polymer Capable of Inducing Hyper-crosslinking-induced Apoptosis in Non-Hodgkin's Lymphoma" The 4th Asia-Pacific International Academy of Pathology (IAP) Congress, IAP (2005)
  • "The generation of a novel Rituximab Polymer which leads to CD20 hyper-crosslinking-induced apoptosis in non-hodgkin‘s Lymphomas" American Association for Cancer Research (AACR) Annual Meeting,, American Association for Cancer Research (AACR), (2005)
  • "Generation of Rituximab Polymer and Evaluation of CD20 Hyper-crosslinking-induced Apoptosis in Non-Hodgkin's Lymphoma" International Society of Biological Therapy Annual Meeting, ISBT (2004)

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

Contact Information

Buffalo General Hospital
Department of Pathology
Buffalo, NY 14203
Phone: (716) 859-2434
Fax: 3168592393

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB Jacobs School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile